Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Expert Opinion on Drug Metabolism & Toxicology|January 12, 2019
Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatmentDiego Bagnasco, Enrico Heffler, Elisa Testino, et al.Biomed Research International|December 7, 2018
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled AsthmaDiego Bagnasco, Marco Caminati, Matteo Ferrando, et al.Respiratory Medicine|January 6, 2025
Background therapy in severe asthma on monoclonal antibody treatment in real lifeFilippo F Cosini, Diego Bagnasco, Fulvio Braido, et al.Journal of Personalized Medicine|April 23, 2022
Specific Therapy for T2 AsthmaDiego Bagnasco, Elisa Testino, Stefania Nicola, et al.Biomedicines|July 29, 2025
Carbon Footprint Impact, of Monoclonal Antibodies for Severe Asthma, Administered in ItalyDiego Bagnasco, Laura Pini, Benedetta Bondi, et al.The World Allergy Organization Journal|December 6, 2021
Severe asthma: One disease and multiple definitionsDiego Bagnasco, Pierluigi Paggiaro, Manuela Latorre, et al.Pulmonary Pharmacology & Therapeutics|September 2, 2019
One year of mepolizumab. Efficacy and safety in real-life in ItalyDiego Bagnasco, Marco Caminati, Francesco Menzella, et al.Biomedicines|September 28, 2023
Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super RespondersDiego Bagnasco, Stefania Nicola, Elisa Testino, et al.Pageof 1